Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Robinson

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
Science Translational Medicine|March 21, 2014
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccinesAmy W Chung, Musie Ghebremichael, Hannah Robinson, et al.
The Journal of Infectious Diseases|August 15, 2020
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU)Kimberley Jefferies, Simon B Drysdale, Hannah Robinson, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
Molecular Plant|October 24, 2017
VERNALIZATION1 Modulates Root System Architecture in Wheat and BarleyKai P Voss-Fels, Hannah Robinson, Stephen R Mudge, et al.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Journal of Infectious Diseases|July 16, 2024
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in CommunitiesDima El Safadi, Lisa Hitchins, Ashleigh Howard, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Science Translational Medicine|March 21, 2014
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccinesAmy W Chung, Musie Ghebremichael, Hannah Robinson, et al.
The Journal of Infectious Diseases|August 15, 2020
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU)Kimberley Jefferies, Simon B Drysdale, Hannah Robinson, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
Molecular Plant|October 24, 2017
VERNALIZATION1 Modulates Root System Architecture in Wheat and BarleyKai P Voss-Fels, Hannah Robinson, Stephen R Mudge, et al.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Journal of Infectious Diseases|July 16, 2024
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in CommunitiesDima El Safadi, Lisa Hitchins, Ashleigh Howard, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Pageof 11